Researchers have developed the basis for a new class of oral drugs derived from the venom of the cone snail that they say could be used to treat chronic nerve pain with fewer side effects than morphine.
Israel's Oramed touted results from a successful Phase IIa trial of its insulin pill, saying the oral Type 2 diabetes treatment is safe and well-tolerated. But since then, some analysts and media outlets have criticized the company for being less than forthcoming about the data.
Delivery company MonoSol Rx is collaborating with BiondVax Pharmaceuticals to develop an oral flu vaccine in a thin film that melts in the mouth in less than 20 seconds, creating a dose that could be stable enough to be mailed out to patients.
Privately held biopharma Chiasma has closed a $38.5 million equity financing and will use the funding to complete the pivotal Phase III trial of Octreolin, an oral formulation of the peptide octreotide in development for the treatment of acromegaly. The clinical trial is expected to complete in the second quarter of 2013.
Canada's Intellipharmaceutics International ($IPCI), a specialist in controlled-release drug formulations, is raising $5 million to fuel anticipated U.S. clinical trials for Rexista, a patented version of the highly addictive pain killer oxycodone designed to resist abuse.
British drug developer GW Pharmaceutical will debut its cannabis-based pain therapy Sativex in Austria as a treatment for MS-related spasticity sometime in 2012, following regulatory approval
Adding a new long-term inhaled dry powder version of mannitol to standard therapy helps improve lung function in cystic fibrosis patients for up to a year, according to a new study. But the forced
Unigene Laboratories ($UGNE) says it has regained the global rights to an oral formulation of a parathyroid hormone analog to treat osteoporosis in postmenopausal women from GlaxoSmithKline ($GSK).
To answer the question we raised in last week's issue of FierceDrugDelivery: Yes, the third time was a charm for Transcept ($TSPT) in its quest for FDA approval of its sleep drug. U.S. regulators
Novartis Pharma's ($NVS) oral formulation of calcitonin to treat for post-menopausal osteoporosis failed to meet its primary endpoint or key secondary endpoints in a crucial critical trial....